Pridopidine, a selective Sigma-1 receptor (S1R) agonist promotes neuroprotection in ALS models

被引：0

作者：

Geva, Michal ^{[1
]}

Wang, Shao-Ming ^{[2
,3
,5
]}

Wu, Hsiang-En ^{[2
,4
]}

Ankol, Lior ^{[6
,7
]}

Ionescu, Ariel ^{[6
,7
]}

Gradus-Pery, Tal ^{[6
,7
]}

Gershoni-Emek, Noga ^{[1
]}

Goldberg, Y. Paul ^{[1
]}

Su, Tsung-Ping ^{[2
]}

Perlson, Eran ^{[6
,7
]}

Hayden, Michael R. ^{[1
,8
]}

机构：

[1] Prilenia Therapeut, Herzliyya, Israel

[2] Natl Inst Drug Abuse, Natl Inst Hlth, Cellular Pathobiol Sect, Integrat Neurosci Res Branch,Intramural Res Progr, Baltimore, MD USA

[3] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan

[4] China Med Univ, Neurosci & Brain Dis Ctr, Taichung, Taiwan

[5] China Med Univ Hosp, Dept Neurol, Taichung, Taiwan

[6] Sagol Sch Neurosci, Tel Aviv, Israel

[7] Sackler Sch Med, Tel Aviv, Israel

[8] Univ British Columbia, CMMT, Vancouver, BC, Canada

来源：

MUSCLE & NERVE | 2022年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S4 / S5

页数：2

共 50 条

[31] Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
Furuse, Tsutomu
Hashimoto, Kenji
ANNALS OF GENERAL PSYCHIATRY, 2010, 9
[32] Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
Tsutomu Furuse
Kenji Hashimoto
Annals of General Psychiatry, 9
[33] Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)
Mavlyutov, Timur A.
Guo, Lian-Wang
Epstein, Miles L.
Ruoho, Arnold E.
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 127 (01) : 10 - 16
[34] The Sigma-1 Receptor-A Therapeutic Target for the Treatment of ALS?
Mavlyutov, Timur A.
Baker, Erin M.
Losenegger, Tasher M.
Kim, Jaimie R.
Torres, Brian
Epstein, Miles L.
Ruoho, Arnold E.
SIGMA RECEPTORS: THEIR ROLE IN DISEASE AND AS THERAPEUTIC TARGETS, 2017, 964 : 255 - 265
[35] LACK OF SIGMA-1 RECEPTOR EXACERBATES ALS PROGRESSION IN MICE
Mavlyutov, T. A.
Epstein, M. L.
Verbny, Y. I.
Huerta, M. S.
Zaitoun, I.
Ziskind-Conhaim, L.
Ruoho, A. E.
NEUROSCIENCE, 2013, 240 : 129 - 134
[36] Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki
Hashimoto, Yaeko
Suzuki, Takuji
Hashimoto, Kenji
MOLECULAR PSYCHIATRY, 2022, 27 (09) : 3563 - 3564
[37] Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
Yaeko Hashimoto
Takuji Suzuki
Kenji Hashimoto
Molecular Psychiatry, 2022, 27 : 3563 - 3564
[38] The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
Ryskamp, Daniel
Wu, Jun
Geva, Michal
Kusko, Rebecca
Grossman, Iris
Hayden, Michael
Bezprozvanny, Ilya
NEUROBIOLOGY OF DISEASE, 2017, 97 : 46 - 59
[39] Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis
Hashimoto, Kenji
BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2024, 37
[40] Clinical implications of using fluvoxamine, a sigma-1 receptor agonist
Hashimoto, K.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 250 - 250

← 1 2 3 4 5 →